Medlab second NanaBis trial approval

AUSTRALIAN LISTED medical life sciences company, Medlab Clinical (MDC) has received Human Ethics approval for a second NanaBis trial, which will be an observational study.

NanaBis is Medlab’s patented, cannabis-based medicine, presently being trialled at Royal North Shore Hospital in Sydney.

The data collected from the new study is aimed at providing support in accelerating the regulatory process.

Medlab aims to roll this trial out to 2,000 patients, making it one of the most significant cannabis trials to date.

Medlab CEO, Dr Sean Hall, explained, “This trial is very important to us as it allows MDC to leverage the Australian Special Access Scheme (SAS), follow the patients closely, but more-so publish and use the forth-coming data to bolster all our regulatory efforts as it relates to NanaBis.”

Costs will be partly met by participants who are given NanaBis at a reduced price.